Drugs with a narrow therapeutic index (NTI) can cause mortality. For these drugs, small differences in concentrations may lead to serious toxicities or therapeutic failures. Consequently, in the setting of generic drug development, it is critical that NTI generic drugs achieve exposures similar to reference products. To enhance the therapeutic equivalence of drugs with NTI, the Food and Drug Administration has tightened their bioequivalence standards. However, broad implementation of these new standards is challenging because some drugs do not have an established NTI classification. This can be due to a lack in characterization of the drugs'therapeutic range or dose/concentration-response relationship. Therefore, there is an urgent and unmet need for a systematic approach to identify and classify drugs with a NTI. This proposal will use a unique infrastructure to integrate clinical practice data with statistical tools to characterize the drug dose/concentration- response relationship and classify drugs with NTI. The central hypothesis of this proposal is that the proposed systematic approach will result in successful classification of drugs with a NTI. Dr. Cohen-Wolkowiez will evaluate this hypothesis by performing a comprehensive search of publicly available data (literature and databases) to extract information and allow classification of drugs with NTI. Because the amount of detail included in publicly available databases is variable, Dr. Cohen-Wolkowiez will supplement this data with information extracted from medical records at the Duke University Medical Center. If sufficient data is available from these two sources, he will then characterize the concentration-response relationship of candidate drugs with NTI using population pharmacokinetics (PK)-pharmacodynamic (PD) methodologies. This project evaluates a novel, systematic approach to classify drugs with NTI. If the combination of publicly available data, supplemental data from medical records, and population PK-PD methodologies can classify drugs with NTI, this will substantially affect public health and streamline applicability of new FDA standards for bioequivalence of generic drugs with NTI.

Public Health Relevance

The proposed project will evaluate the use of clinical practice data to classify drugs with narrow therapeutic index. This goal will be accomplished using a comprehensive search of the medical literature, publicly available databases, and medical records in combination with statistical tools (population pharmacokinetic (PK)/pharmacodynamics (PD) models) that can characterize the drug concentration-response relationship to classify drugs with narrow therapeutic index. This classification will result in a drug list that will be used by the Food and Drug Administration to evaluate new bioequivalence standards of generic products with narrow therapeutic index.

Agency
National Institute of Health (NIH)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01FD004858-01S1
Application #
8890533
Study Section
Special Emphasis Panel (ZFD1)
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Duke University
Department
Pediatrics
Type
Schools of Medicine
DUNS #
City
Durham
State
NC
Country
United States
Zip Code
27705
Gostelow, Martyn; Gonzalez, Daniel; Smith, P Brian et al. (2014) Pharmacokinetics and safety of recently approved drugs used to treat methicillin-resistant Staphylococcus aureus infections in infants, children and adults. Expert Rev Clin Pharmacol 7:327-40
Cohen-Wolkowiez, Michael; Benjamin Jr, Daniel K (2014) Editorial commentary: Fluconazole therapeutic drug monitoring in children with cancer: not today. Clin Infect Dis 59:1534-6
Sampson, Mario R; Frymoyer, Adam; Rattray, Benjamin et al. (2014) Predictive performance of a gentamicin population pharmacokinetic model in neonates receiving full-body hypothermia. Ther Drug Monit 36:584-9
Tremoulet, Adriana; Le, Jennifer; Poindexter, Brenda et al. (2014) Characterization of the population pharmacokinetics of ampicillin in neonates using an opportunistic study design. Antimicrob Agents Chemother 58:3013-20
Gonzalez, Daniel; Paul, Ian M; Benjamin Jr, Daniel K et al. (2014) Advances in pediatric pharmacology, therapeutics, and toxicology. Adv Pediatr 61:7-31
Gonzalez, D; Melloni, C; Yogev, R et al. (2014) Use of opportunistic clinical data and a population pharmacokinetic model to support dosing of clindamycin for premature infants to adolescents. Clin Pharmacol Ther 96:429-37
Sampson, Mario R; Bloom, Barry T; Lenfestey, Robert W et al. (2014) Population pharmacokinetics of intravenous acyclovir in preterm and term infants. Pediatr Infect Dis J 33:42-9
Beam, Kristyn S; Laughon, Matthew M; Hornik, Christoph P et al. (2014) Predictors of positive cerebrospinal fluid cultures in infants with bacteremia. Pediatr Infect Dis J 33:360-5